Product Description.:
CZ
capsule , tan , oblong oblong
Black ink
COLAZAL (balsalazide disodium) is a treatment for a condition called ulcerative colitis?or UC for short. COLAZAL is approved by the FDA to deliver relief of symptoms caused by mildly to moderately active ulcerative colitis.
UC is 1 of 2 types of inflammatory bowel disease (IBD), the other being Crohn's disease. Ulcerative colitis is characterized by inflammation and ulceration of the lining of the colon. The cause is unknown, and it usually occurs in people aged 15 to 35 years, with a second peak among people aged 55 to 60 years. UC symptoms may include bloody diarrhea, rectal bleeding, bowel urgency, abdominal pain and tenderness, nausea and vomiting, loss of appetite, weight loss, and fever.
COLAZAL is a UC treatment that has been clinically proven to provide complete relief of symptoms in an average of 10 days.1 COLAZAL is unlike other kinds of ulcerative colitis medications because it delivers 99% of its active ingredient (balsalazide disodium) to the colon to start working to relieve UC symptoms.2
To learn more about COLAZAL, inflammatory bowel disease, and living with UC, browse the menu to the left or speak to your healthcare provider.
COLAZAL? (balsalazide disodium) Capsules 750 mg are indicated for the treatment of mildly to moderately active Ulcerative Colitis in patients 5 years of age and older. COLAZAL does not relieve symptoms in all patients your patients' results may vary. In four well-controlled clinical trials, patients receiving a COLAZAL dose of 6.75g/day most frequently reported the following events (reporting frequency > 3%): headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to placebo. In the pediatric trial, patients most frequently reported the following adverse events: headache (15%), abdominal pain upper (13%), abdominal pain (12%), vomiting (10%), diarrhea (9%), colitis ulcerative (6%), nasopharyngitis (6%) and, pyrexia (6%). COLAZAL is contraindicated in patients with a hypersensitivity to salicylates or the components of COLAZAL capsules or balsalazide metabolites. The safety and effectiveness of COLAZAL beyond 8 weeks in children (ages 5-17 years) and 12 weeks in adults have not been established.
Consult with your physician to see if this product is right for you.